Log in

NASDAQ:XLRNAcceleron Pharma Competitors & Alternatives

$101.35
+5.07 (+5.27 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$97.52
Now: $101.35
$104.18
50-Day Range
$90.94
MA: $98.05
$104.80
52-Week Range
$37.60
Now: $101.35
$110.49
Volume1.51 million shs
Average Volume1.08 million shs
Market Capitalization$5.46 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.74

Competitors

Acceleron Pharma (NASDAQ:XLRN) Vs. MRNA, BNTX, NBIX, ARGX, TECH, and QGEN

Should you be buying XLRN stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Acceleron Pharma, including Moderna (MRNA), BioNTech (BNTX), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), and Qiagen (QGEN).

Moderna (NASDAQ:MRNA) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Institutional & Insider Ownership

52.0% of Moderna shares are owned by institutional investors. Comparatively, 88.5% of Acceleron Pharma shares are owned by institutional investors. 29.2% of Moderna shares are owned by insiders. Comparatively, 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Moderna and Acceleron Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Moderna01902.90
Acceleron Pharma111102.77

Moderna currently has a consensus target price of $65.9091, suggesting a potential upside of 12.53%. Acceleron Pharma has a consensus target price of $118.00, suggesting a potential upside of 16.43%. Given Acceleron Pharma's higher possible upside, analysts plainly believe Acceleron Pharma is more favorable than Moderna.

Profitability

This table compares Moderna and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Moderna-963.84%-37.49%-29.24%
Acceleron Pharma-182.31%-30.14%-27.01%

Earnings and Valuation

This table compares Moderna and Acceleron Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moderna$60.21 million361.11$-514,020,000.00($1.55)-37.79
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58

Acceleron Pharma has higher revenue and earnings than Moderna. Acceleron Pharma is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Moderna has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Summary

Acceleron Pharma beats Moderna on 9 of the 14 factors compared between the two stocks.

BioNTech (NASDAQ:BNTX) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares BioNTech and Acceleron Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNTech$121.63 million117.70$-200,540,000.00($0.95)-66.60
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58

Acceleron Pharma has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Acceleron Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioNTech and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioNTechN/AN/AN/A
Acceleron Pharma-182.31%-30.14%-27.01%

Analyst Ratings

This is a breakdown of recent recommendations for BioNTech and Acceleron Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioNTech05302.38
Acceleron Pharma111102.77

BioNTech currently has a consensus target price of $43.5556, suggesting a potential downside of 31.16%. Acceleron Pharma has a consensus target price of $118.00, suggesting a potential upside of 16.43%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Acceleron Pharma is more favorable than BioNTech.

Institutional & Insider Ownership

2.9% of BioNTech shares are owned by institutional investors. Comparatively, 88.5% of Acceleron Pharma shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Acceleron Pharma beats BioNTech on 7 of the 13 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

Acceleron Pharma has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Earnings & Valuation

This table compares Acceleron Pharma and Neurocrine Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58
Neurocrine Biosciences$788.10 million14.77$37.01 million$0.39321.46

Neurocrine Biosciences has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acceleron Pharma and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-182.31%-30.14%-27.01%
Neurocrine Biosciences19.90%37.53%18.29%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acceleron Pharma and Neurocrine Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma111102.77
Neurocrine Biosciences051302.72

Acceleron Pharma presently has a consensus price target of $118.00, suggesting a potential upside of 16.43%. Neurocrine Biosciences has a consensus price target of $127.7647, suggesting a potential upside of 1.91%. Given Acceleron Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe Acceleron Pharma is more favorable than Neurocrine Biosciences.

Insider and Institutional Ownership

88.5% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 96.8% of Neurocrine Biosciences shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Neurocrine Biosciences beats Acceleron Pharma on 11 of the 14 factors compared between the two stocks.

Acceleron Pharma (NASDAQ:XLRN) and argenx (NASDAQ:ARGX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.

Volatility & Risk

Acceleron Pharma has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, argenx has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500.

Earnings & Valuation

This table compares Acceleron Pharma and argenx's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58
argenx$78.17 million137.55$-182,520,000.00($4.73)-48.36

Acceleron Pharma has higher earnings, but lower revenue than argenx. argenx is trading at a lower price-to-earnings ratio than Acceleron Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acceleron Pharma and argenx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acceleron Pharma-182.31%-30.14%-27.01%
argenxN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Acceleron Pharma and argenx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acceleron Pharma111102.77
argenx021402.88

Acceleron Pharma presently has a consensus price target of $118.00, suggesting a potential upside of 16.43%. argenx has a consensus price target of $220.40, suggesting a potential downside of 3.64%. Given Acceleron Pharma's higher possible upside, research analysts plainly believe Acceleron Pharma is more favorable than argenx.

Insider and Institutional Ownership

88.5% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 54.5% of argenx shares are owned by institutional investors. 2.5% of Acceleron Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

argenx beats Acceleron Pharma on 8 of the 14 factors compared between the two stocks.

BIO-TECHNE (NASDAQ:TECH) and Acceleron Pharma (NASDAQ:XLRN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Earnings and Valuation

This table compares BIO-TECHNE and Acceleron Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BIO-TECHNE$714.01 million14.41$96.07 million$3.8070.84
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58

BIO-TECHNE has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

BIO-TECHNE has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BIO-TECHNE and Acceleron Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BIO-TECHNE04502.56
Acceleron Pharma111102.77

BIO-TECHNE presently has a consensus price target of $245.50, indicating a potential downside of 8.80%. Acceleron Pharma has a consensus price target of $118.00, indicating a potential upside of 16.43%. Given Acceleron Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Acceleron Pharma is more favorable than BIO-TECHNE.

Insider & Institutional Ownership

95.7% of BIO-TECHNE shares are owned by institutional investors. Comparatively, 88.5% of Acceleron Pharma shares are owned by institutional investors. 4.2% of BIO-TECHNE shares are owned by insiders. Comparatively, 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BIO-TECHNE and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BIO-TECHNE24.77%13.04%8.13%
Acceleron Pharma-182.31%-30.14%-27.01%

Summary

BIO-TECHNE beats Acceleron Pharma on 10 of the 14 factors compared between the two stocks.

Qiagen (NYSE:QGEN) and Acceleron Pharma (NASDAQ:XLRN) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Qiagen and Acceleron Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qiagen$1.53 billion6.34$-41,460,000.00$1.4329.73
Acceleron Pharma$73.99 million73.74$-124,860,000.00($2.38)-42.58

Qiagen has higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Qiagen has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Acceleron Pharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Qiagen and Acceleron Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Qiagen114602.24
Acceleron Pharma111102.77

Qiagen presently has a consensus price target of $37.00, indicating a potential downside of 12.96%. Acceleron Pharma has a consensus price target of $118.00, indicating a potential upside of 16.43%. Given Acceleron Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Acceleron Pharma is more favorable than Qiagen.

Insider and Institutional Ownership

60.2% of Qiagen shares are owned by institutional investors. Comparatively, 88.5% of Acceleron Pharma shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 2.5% of Acceleron Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Qiagen and Acceleron Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Qiagen-2.01%13.80%6.68%
Acceleron Pharma-182.31%-30.14%-27.01%

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MRNA
Moderna
1.6$58.57+5.2%$21.74 billion$60.21 million-39.05
BNTX
BioNTech
0.9$63.27+1.4%$14.32 billion$121.63 million-66.60Analyst Upgrade
Unusual Options Activity
Heavy News Reporting
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
1.8$125.37+0.4%$11.64 billion$788.10 million68.14
argenx logo
ARGX
argenx
1.2$228.72+0.4%$10.75 billion$78.17 million-48.36
BIO-TECHNE logo
TECH
BIO-TECHNE
1.7$269.18+1.2%$10.29 billion$714.01 million56.91
Qiagen logo
QGEN
Qiagen
0.9$42.51+0.5%$9.68 billion$1.53 billion-265.69
Repligen logo
RGEN
Repligen
1.2$126.65+1.9%$6.62 billion$270.24 million281.45Analyst Report
Analyst Revision
ADPT
Adaptive Biotechnologies
1.1$47.49+0.6%$6.03 billion$85.07 million-26.98Analyst Downgrade
Insider Selling
ALLO
Allogene Therapeutics
1.3$44.96+5.2%$5.63 billionN/A-22.59Insider Selling
Crispr Therapeutics logo
CRSP
Crispr Therapeutics
1.2$79.70+1.5%$4.94 billion$289.59 million106.27
Novavax logo
NVAX
Novavax
1.2$81.64+2.4%$4.73 billion$18.66 million-19.72Analyst Downgrade
Analyst Revision
Spark Therapeutics logo
ONCE
Spark Therapeutics
1.1$113.57+0.0%$4.37 billion$64.72 million-53.82
China Biologic Products logo
CBPO
China Biologic Products
0.6$104.19+2.1%$4.10 billion$503.70 million26.38
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.6$28.51+3.9%$3.87 billion$195.99 million-51.84Analyst Report
Unusual Options Activity
Momenta Pharmaceuticals logo
MNTA
Momenta Pharmaceuticals
1.6$32.27+1.5%$3.80 billion$23.87 million-11.52Analyst Downgrade
Insider Selling
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$29.09+0.2%$3.69 billionN/A-15.90
bluebird bio logo
BLUE
bluebird bio
1.5$59.50+2.6%$3.31 billion$44.67 million-3.98Analyst Revision
Fate Therapeutics logo
FATE
Fate Therapeutics
1.7$36.21+0.2%$2.81 billion$10.68 million-23.06Analyst Downgrade
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.2$25.45+0.8%$2.69 billion$26.68 million-11.57Analyst Downgrade
Insider Selling
Analyst Revision
TWST
Twist Bioscience
1.1$46.16+1.5%$1.89 billion$54.38 million-10.44Analyst Upgrade
ALEC
Alector
1.4$23.81+4.8%$1.88 billion$21.22 million-13.15Analyst Downgrade
RVMD
Bill.com
1.7$31.01+5.0%$1.83 billionN/A0.00
SWTX
SpringWorks Therapeutics
1.3$40.55+2.0%$1.74 billionN/A-11.42Heavy News Reporting
Editas Medicine logo
EDIT
Editas Medicine
1.3$30.53+1.0%$1.69 billion$20.53 million-10.98
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.0$20.82+1.2%$1.67 billion$250,000.00-19.28Analyst Downgrade
BEAM
Beam Therapeutics
0.6$28.87+1.2%$1.49 billion$20,000.00-2.05
BDTX
I-Mab
1.3$41.02+5.0%$1.47 billionN/A-2.41Analyst Downgrade
Heavy News Reporting
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.4$6.85+1.2%$1.44 billion$31.43 million-3.94Analyst Downgrade
Regenxbio logo
RGNX
Regenxbio
1.5$38.10+1.7%$1.42 billion$35.23 million-13.71
Mesoblast logo
MESO
Mesoblast
1.2$12.04+3.8%$1.40 billion$16.72 million-18.81Analyst Downgrade
Analyst Revision
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.4$9.63+2.6%$1.36 billion$102.43 million-11.60Analyst Downgrade
CRTX
Cortexyme
2.0$45.89+3.5%$1.35 billionN/A-22.83Analyst Downgrade
NanoString Technologies logo
NSTG
NanoString Technologies
0.9$35.03+7.6%$1.32 billion$125.57 million-21.36Heavy News Reporting
Coherus Biosciences logo
CHRS
Coherus Biosciences
1.5$18.30+0.3%$1.30 billion$356.07 million9.34
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
0.9$9.79+2.0%$1.27 billion$1.12 million-7.47
PASG
Passage Bio
1.2$26.15+0.3%$1.19 billionN/A0.00
Nantkwest logo
NK
Nantkwest
1.3$11.99+2.1%$1.18 billion$40,000.00-17.63Analyst Downgrade
TBIO
Translate Bio
1.4$17.86+2.3%$1.12 billion$7.80 million-10.51Analyst Upgrade
Insider Buying
Compugen logo
CGEN
Compugen
1.4$15.40+4.3%$1.05 billion$17.80 million-38.50Analyst Downgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$5.02+2.2%$885.53 million$48.83 million-5.34Analyst Downgrade
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.5$14.68+2.4%$865.42 millionN/A-2.68Analyst Report
Replimune Group logo
REPL
Replimune Group
1.5$22.16+3.6%$815.05 millionN/A-14.58Analyst Report
Cellectis logo
CLLS
Cellectis
1.3$18.65+3.2%$791.98 million$22.99 million-11.80
Krystal Biotech logo
KRYS
Krystal Biotech
1.4$44.75+1.6%$778.02 millionN/A-36.09
Vericel logo
VCEL
Vericel
1.7$15.11+1.6%$681.62 million$117.85 million-53.96Analyst Upgrade
Unusual Options Activity
Agenus logo
AGEN
Agenus
1.5$4.02+0.0%$672.87 million$150.05 million-3.24Analyst Downgrade
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.6$13.97+3.5%$649.16 million$69.89 million-3.17
RCEL
AVITA MED LTD/S
1.0$30.00+2.1%$644.04 million$5.51 million-15.38Analyst Downgrade
Avrobio logo
AVRO
Avrobio
1.4$17.77+0.3%$640.35 millionN/A-6.51Analyst Downgrade
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$28.01+0.7%$625.45 millionN/A-24.36
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.